Novo Nordisk shares fall about 10% after negative phase 3 trial news on Ziltivekimab

Fri 31 Jul 2026 13:28 CEST

Danish pharmaceutical giant Novo Nordisk is plunging by around 10 percent on the Copenhagen Stock Exchange after negative news regarding a phase 3 clinical trial linked to the drug candidate Ziltivekimab.

Author

TT News AgencyEnglish edition by Sweden Herald, adapted for our readers

Was this useful?

What do you think?

Most read right now

1Denmark’s 71 Million Kroner for Ukraine’s Artillery Shells Went to Italian Software Firm 2Norway’s Public Toilet Campaign Goes Viral After Trump Calls Country a ‘Shithole’3Man dies in accident involving weights at Sats gym in Oslo 4Protests Erupt in Warsaw After Poland’s Constitutional Court President Is Suspended 5Villa Vie Odyssey Owner Says He Feels Terrible as Passengers Are Stranded in Cambodia

More on Business

Binance to cover losses after $6.2 billion crypto theft, resume withdrawals Sunday

6 h ago

Extreme heat is forcing H&M to rethink clothing and collection timing

12 h ago

OpenAI Falls Short of $30 Billion Fundraising Target as Investors Commit Less Than Half

OpenAI Raises Less Than Half of $30 Billion Investment Goal, WSJ Reports

13 h ago

Riksbank Rate Hike Expected Wednesday as Economists Warn of Tougher Times for Households

14 h ago

Meta settles with 18-year-old over Instagram’s allegedly harmful algorithms days before trial

1 d ago

Memorial ground the evening before All saints' day. Hedemora cemetery, Sweden.

Swedish Halloween spending forecast at 1.2 billion kronor

1 d ago

Technology

FBI Blames North Korean Hackers for $6.3 Billion Binance Crypto Heist

just now

Keep readingmore from Business

All